While our patient presented with EGFR-mutant circulating tumor cells (CTCs) and showed a favorable response to EGFR TKIs, we were unable to validate this finding with molecular-based EGFR mutation profiling (e.g., polymerase chain reaction or next-generation sequencing) of the tumor biopsy. Here, EGFR is linked to neoplasm.